Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | CNR2 | P34972 | 2/20 | 0.61 |
| ▸ | TP53 | P04637 | 2/20 | 0.61 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | CNR1 | P21554 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2936007 | 0.93 | CNR2 (0.62) | LMNACNR2TP53CHRM1 | |
| SCHEMBL2938668 | 0.93 | DNTT (0.62) | LMNATP53CHRM1 | |
| SCHEMBL2935928 | 0.92 | TP53 (0.71) | LMNACNR2TP53CHRM1 | |
| SCHEMBL2937096 | 0.92 | LMNA (0.60) | LMNACNR2TP53CHRM1CNR1 | |
| SCHEMBL2937922 | 0.89 | LMNA (0.57) | LMNACNR2TP53CHRM1L3MBTL1 | |
| SCHEMBL2936946 | 0.89 | LMNA (0.57) | LMNATP53CHRM1 | |
| SCHEMBL2933160 | 0.89 | CHRM1 (0.76) | LMNACHRM1 | |
| SCHEMBL2937596 | 0.87 | LMNA (0.55) | LMNACNR2TP53CHRM1 | |
| SCHEMBL2966443 | 0.86 | MAPT (0.67) | LMNACNR2TP53CHRM1CNR1 | |
| SCHEMBL2937566 | 0.85 | LMNA (0.61) | LMNACNR2TP53CHRM1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730135-B1 | QIUNOLIN-4-ONES AS INHIBITORS OF RETROVIRAL INTEGRASE FOR THE TREATMENT OF HIV, AIDS AND AIDS RELATED COMPLEX (ARC) | US OF AMERICA REPRESENTED BY T (US) | 2010-09-22 | — | — | EP | disclosed |
| US-7776883-B2 | Quinolin-4-ones as inhibitors of retroviral integrase for the treatment of HIV, AIDS and AIDS related complex (ARC) | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-08-17 | — | — | US | disclosed |
| US-20070219242-A1 | Quinolin-4-Ones as Inhibitors of Retroviral Integrase for the Treatment of Hiv, Aids and Aids Related Complex (Arc) | GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219242-A1 | Quinolin-4-Ones as Inhibitors of Retroviral Integrase for the Treatment of Hiv, Aids and Aids Related Complex (Arc) | QTRT1, QTRT2, CTCF | LMNA 4260/4885CNR2 4590/4885TP53 3949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.